Europa Press Madrid
Madrid
Updated Friday, March 22, 2024-09:29
Grifols
shares
soared almost 8% on the stock market this Friday around 9:10 a.m. following the report from the
National Securities Market Commission (CNMV)
released this Thursday. Thus, the blood products company led the rise of the
Ibex 35
with a rise of 7.86%, until its shares were exchanged at a unit price of 9.084 euros.
In the document, the CNMV has found "relevant deficiencies" in Grifols' annual accounts, specifically in the detail and accuracy of the breakdowns and explanatory notes that support the figures, although the supervisor has pointed out that it has not identified "
significant errors"
in the results, so it has not currently identified the need to carry out any reformulation of its financial statements.
For its part, Grifols, in response to the CNMV, has assured that it is committed to improving its transparency and expanding the breakdowns of its financial information following the regulator's recommendations.
Regarding these deficiencies, the supervisory body has referred to the financial information in some years of the period analyzed and in the presentation of alternative performance measures (APM), in particular the gross operating result (Ebitda ) and the debt/Ebitda ratio.
To know more
Grifols.
The CNMV sees "relevant deficiencies" in Grifols' financial information, but does not ask it to redo its accounts
Editorial: EL MUNDO
The CNMV sees "relevant deficiencies" in Grifols' financial information, but does not ask it to redo its accounts
Companies.
Who is who in Grifols, the pharmaceutical company that acted as a bank for the Catalan family
Editor: LAURA DE LA QUINTANA Madrid
Who is who in Grifols, the pharmaceutical company that acted as a bank for the Catalan family
At the same time, the CNMV has indicated that it has not found evidence that allows it to conclude that the
financial debt
reflected by Grifols does not correspond to reality.
"These deficiencies, although they are complex to assess individually and separately, as a whole must be considered significant, to the extent that they have hindered in some years the ability of investors to adequately understand the financial situation, results and cash flows of the issuer. ", as assessed by the CNMV.
The most relevant deficiency consists, in the supervisor's opinion, in the use of adjusted Ebitda without excluding the results attributable to non-controlled interests when explaining the financial leverage ratio of the
Grifols group
and its financial capacity to satisfy the debt.
As he has pointed out, this is not in accordance with the legal obligations to reflect "useful, relevant, objective and neutral" information. Additionally, Grifols did not publish the information necessary for investors to calculate Ebitda excluding said results attributable to non-controlled interests.